The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price decrease of -40.66%. However, over the past six months, we’ve seen a stronger performance of -36.69%. The price of DNLI leaped by -10.01% over the last 30 days. And in the last five days, it has fallen by -7.49%.
The stock price for Denali Therapeutics Inc (DNLI) currently stands at $13.22. The stock experienced a substantial increase in the last session, hitting $40.0 after starting at $13.22. The stock’s lowest price was $24.0 before closing at $13.92.
The market performance of Denali Therapeutics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $33.33 on 11/11/24, while the lowest value for the same duration was $10.57 on 04/07/25.
52-week price history of DNLI Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Denali Therapeutics Inc’s current trading price is -60.34% away from its 52-week high, while its distance from the 52-week low is 25.07%. The stock’s price range during this period has varied between$10.57 and $33.33. The Denali Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.98 million for the day, a figure considerably higher than their average daily volume of 1.56 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Denali Therapeutics Inc (DNLI) has experienced a quarterly decline of -10.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.92B and boasts a workforce of 422 employees.
Denali Therapeutics Inc: Analysts’ Ratings Unveiled
As of right now, 16 analysts are rating Denali Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 14.13, with a change in price of -1.60. Similarly, Denali Therapeutics Inc recorded 1,567,360 in trading volume during the last 100 days, posting a change of -10.80%.
DNLI’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for DNLI stands at 0.05. Similarly, the long-term debt-to-equity ratio is also 0.04.
DNLI Stock Stochastic Average
As of today, Denali Therapeutics Inc’s raw stochastic average for the last 50 days stands at 10.99%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 13.65%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 28.76% and 37.93%, respectively.
